Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Focus on motor neurone disease

Motor neurone disease (MND), also known as amyotrophic lateral sclerosis, is a degenerative disease of unknown cause which causes patients to lose basic motor functions and has a devastating effect on them and their families.

17 Jun 2007

In vivo imaging of siRNA delivery and silencing in tumors

Using magnetic nanoparticles labeled with dye molecules, a team of investigators at the Massachusetts General Hospital has developed a delivery vehicle capable of transporting antitumor small interfering RNA (siRNA) molecules into cells.

14 Jun 2007

Hybrid gold-dendrimer nanoparticles target and image tumors

Dendrimer nanoparticles, made of spherical, highly branched polymers, have shown promise as drug delivery vehicles capable of targeting tumors with large doses of anticancer drugs.

14 Jun 2007

New drug-delivery system using nanomaterials

Researchers at UCLA have successfully manipulated nanomaterials to create a new drug-delivery system that promises to solve the challenge of the poor water solubility of today's most promising anticancer drugs and thereby increase their effectiveness.

8 Jun 2007

Designer lipid-like peptides to play a key role in improving drug delivery systems

Scientists from Institute of Biophysics and Nanosystems Research (IBN), Austrian Academy of Sciences and of Centre for Biomedical Engineering, Massachusetts Institute of Technology, Cambridge, USA report the study of Tuning Curvature and Stability of Monoolein Bilayers by Designer Lipid-Like Peptide Surfactants in the May 30th issue of the online, open-access journal PLoS ONE.

30 May 2007

Evaluation of leading combination regimens for treating malaria

Ugandan children who received the combination therapy of artemether-lumefantrine experienced a lower rate of treatment failure compared to other combination therapies, according to a study in the May 23/30 issue of JAMA , a theme issue on malaria.

24 May 2007

Drug eluting nanostructured coatings

Drug delivery systems have progressed from the teaspoon to time-release capsules to drug-eluting stents.

22 May 2007

Clinical trial data for Perforomist Inhalation solution

Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).

22 May 2007

Biomoda files for patent protection for porphyrin molecule

Biomoda, Inc. is expanding its patent portfolio with an additional patent pending for the use of its patented porphyrin molecule as part of a sophisticated cancer drug delivery system.

18 May 2007

Innovative drug-delivery system for rotavirus vaccine

A thin strip that dissolves in the mouth like a popular breath-freshener could someday provide life-saving rotavirus vaccine to infants in impoverished areas.

17 May 2007

FDA approves Dey, L.P.'s NDA for chronic obstructive pulmonary disease inhalation solution

Dey, L.P. has announced that the Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Perforomist (formoterol fumarate) Inhalation Solution for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

15 May 2007

Researchers equip E. coli with a "riboswitch" chemo-navigational system

Using an innovative method to control the movement of Escherichia coli in a chemical environment, Emory University scientists have opened the door to powerful new opportunities in drug delivery, environmental cleanup and synthetic biology.

11 May 2007

Ranbaxy receives approval to manufacture Pravastatin Sodium tablets in U.S.

Ranbaxy Pharmaceuticals has announced that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Pravastatin Sodium Tablets (Pravastatin), 10 mg, 20 mg, 40 mg and 80 mg, with 180-day market exclusivity in the U.S. healthcare system for the 80 mg strength.

27 Apr 2007

Neuromed licenses chronic pain product from ALZA Corporation

Neuromed Pharmaceuticals has announced that it has licensed from ALZA Corporation the exclusive U.S. rights to develop and commercialize OROS(R) Hydromorphone, an extended release formulation of a potent opioid analgesic in Phase 3 clinical development.

25 Apr 2007

Baxter Healthcare presents phase I inhaled insulin study results

Baxter Healthcare Corporation announced results of a Phase I study that evaluated pulmonary insulin produced with Baxter's PROMAXX microsphere technology and administered using a small, standard dry powder inhaler.

24 Apr 2007

ZARS announces Swedish marketing approval for Rapydan

ZARS, Inc. has announced that the Medical Products Agency in Sweden has approved Rapydan 70 mg/70 mg medicated plaster, a topical local anesthetic patch.

20 Apr 2007

Micell Technologies presents data on novel drug-eluting stents

Micell Technologies has announced that the Company will be presenting data on use of its supercritical fluid (SCF) surface modification technology for drug-eluting stents at the upcoming Society for Biomaterials 2007 Annual Meeting, April 19-21 2007 in Chicago, Illinois.

19 Apr 2007

Better understanding of membrane fusion

Cells constantly swap cargo bound in vesicles, miniscule membrane-enclosed packages of proteins and other chemicals. Before the swap can take place, the vesicle membrane must fuse with another membrane, creating channels packages can pass through.

18 Apr 2007

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

15 Apr 2007

Gelatin-based nanoparticles deliver therapeutic genes to human breast cancer

Northeastern University professor Mansoor Amiji and graduate student Sushma Kommareddy have published a new paper that examines the potential of engineered gelatin-based nanoparticles to deliver therapeutic genes to human breast cancer tumors implanted in mice.

14 Apr 2007